Our Team


Stan E. Abel, President and Chief Executive Officer

Stan E. Abel joined SiteOne in February 2014 as President and Chief Executive Officer, bringing to the company more than 20 years of senior management and financial experience.  Mr. Abel's background includes successfully leading complex development-stage life science companies, identifying and in-licensing important new pharmaceutical product opportunities, raising more than $100M in capital to fund operations, and providing strategic advisory services to a wide range of development stage biotech companies.  Mr. Abel currently serves as a member of the board directors of Adynxx, Inc.

Mr. Abel served as Chief Executive Officer of Corthera, Inc., from October 2007 through the successful sale of the company to Novartis in February 2010.  Prior to joining Corthera, he was a founder and Chief Financial Officer of Cerexa, Inc. from its inception in July 2005 through the successful sale of the company to Forest Laboratories in January 2007.  Prior to Cerexa‚ he was the Chief Financial Officer of Peninsula Pharmaceuticals, Inc. from January 2003 through the sale of the company to Johnson & Johnson in June 2005.

Earlier in his career‚ Mr. Abel spent four years at Eli Lilly and Company within the finance and strategy organizations. He also held a variety of financial leadership positions during his nine years at DowBrands‚ Inc., a wholly-owned subsidiary of The Dow Chemical Company.  He earned a B.S. in business from Indiana University and an M.B.A.‚ with honors‚ from the University of Chicago.


Debra Odink, Ph.D., Chief Development Officer

Debra Odink, Ph.D. joined SiteOne in April 2017 as Chief Development Officer.  Dr. Odink brings 25 years of pharmaceutical development and strategic planning experience to the company.  Most recently, Dr. Odink was Senior Vice President at Eiger Biopharmaceuticals where she led Technical Operations for four development programs.  Prior to this, she was the Chief Technical Officer and Senior Vice President at Anthera Pharmaceuticals responsible for manufacturing, clinical and non-clinical operations for the company’s biologic and pharmaceutical programs.  Dr. Odink also served as Vice President of Pharmaceutical Chemistry and Product Development at Peninsula Pharmaceuticals, acquired by Johnson and Johnson in 2005.

Dr. Odink has directed the pharmaceutical development and manufacturing activities for many global development programs, participated in licensing and supply agreement negotiations, due diligence efforts and regulatory strategy meetings with the FDA.  Additionally, Dr. Odink was co-founder of a pharmaceutical services company which has become a well-known provider to many virtual biotech companies.  Earlier in her career, Debra spent 7 years with Roche Pharmaceuticals in a variety of technical positions.  Dr. Odink obtained her Bachelor of Science in Chemistry, at California State University, Stanislaus and her Ph.D. in Inorganic Chemistry at the University of California, Davis.


John Mulcahy, Ph.D., Co-inventor, VP of Research

John Mulcahy Ph.D., is a Co-Founder and Vice President of Research at SiteOne. As a postdoctoral fellow and graduate student at Stanford, he developed methods for preparing a family of rare, naturally occurring sodium ion channel pore blockers from simple starting materials. He received his A.B. degree from Harvard University, with concentrations in Chemistry, Physics, and the Classics. Honors include a Stanford Dean’s Postdoctoral Fellowship, a National Science Foundation Predoctoral Fellowship, a Pfizer Summer Research Fellowship and a National Merit Scholarship. Dr. Mulcahy is also a Principal Investigator on multiple small business grants awarded to SiteOne by The National Institutes of Health.


Hassan Pajouhesh, Ph.D., Director, Chemistry

Hassan Pajouhesh Ph.D., is Director of Chemistry at SiteOne. He has a broad background in organic synthesis and medicinal chemistry and over 17 years of specific training and expertise in the ion channel research area. He has directed successful lead optimization efforts for multiple indications, resulting in clinical candidates and Investigational New Drug (IND) applications. He is author or co-author of more than 22 peer-reviewed publications and a co-inventor on more than 30 issued or pending U.S. patents. Dr. Pajouhesh completed his Ph.D. in the field of organic chemistry at the University of Missouri-Kansas City. He received postdoctoral training at Southern Methodist University where his research contributed to the total synthesis of (+-)-Asparenomycin C.


Anton Delwig, Ph.D., Principal Scientist

Anton Delwig Ph.D., is a Principal Scientist at SiteOne.  He has 12 years of experience in molecular biology, neurophysiology and behavioral studies.  Dr. Delwig is responsible for the biological in-vitro and in-vivo components of the discovery program at SiteOne, which includes electrophysiological measurements of the potencies of novel compounds against Nav isoforms, development of pre-clinical models, and assessment in pilot efficacy and safety studies.  Dr. Delwig earned his Ph.D. in neurobiology from the University of Vermont and completed his post-doctoral training at UC Berkeley and UCSF.  He is a co-Principal Investigator on two small business grants awarded to SiteOne by The National Institutes of Health.


Anne Martin, Controller

Anne McReynolds Martin, CPA, is the Controller of SiteOne Therapeutics.  She has over twenty years of experience in finance and accounting that began in public accounting at a firm just outside of Chicago. Throughout her career, she has held management positions in a variety of industries, both corporate and non-profit, in addition to consulting small and mid-sized businesses.  

Prior to joining SiteOne Therapeutics, Ms. McReynolds Martin served as the Finance and Accounting Manager for Prospera Business Network (Bozeman, Montana).  Earlier in her career, she served as Controller of First Banking Center, Inc. (Burlington, Wisconsin).  

Ms. McReynolds Martin earned her BS in accounting, cum laude, from Northeastern Illinois University in 1992 and became a Certified Public Accountant in 1995.  She attended the Graduate School of Banking program at the University of Wisconsin-Madison.  She is a member of both the AICPA and the Montana Society of CPAs.


John C Hunter, Ph.D., Chief Scientific Officer

John C Hunter joined SiteOne in September 2018 as Chief Scientific Officer with over 30 years of experience as a highly-accomplished pharmaceutical research and development executive, having held multiple senior leadership positions within the pharmaceutical industry from Parke-Davis to Syntex/Roche and then Schering-Plough/Merck. Dr Hunter brings a wealth of expertise in leading complex, inter-disciplinary, drug development teams towards the successful progression of novel therapeutics to improve human health. This work has contributed towards several marketed products across diverse therapeutic categories with many more molecules reaching various stages of clinical development. He is a pharmacologist by training and has a specific interest and expertise in neurodegenerative disease and the contribution of the sensory nervous system to acute and chronic pain. He has contributed more than 100 peer-reviewed publications with several additional reviews and book chapters and is a member of the International Association for the Study of Pain and Society for Neuroscience. He earned a B.Sc. with honors and Ph.D. in Pharmacology from the University of Glasgow, U.K. followed by a Post-Doctoral Fellowship in Neuroscience at the University of Cambridge, U.K.